The prognostic value of high-sensitivity C-reactive protein blood level after coronary stenting for the development of stent restenosis

Aim      To analyze the relationship between serum concentrations of high-sensitivity C-reactive protein (hsCRP) in dynamics and development of restenosis at 12 months following elective coronary stent placement (CSP).

Material and methods  The key role in atherogenesis, neointimal proliferation and restenosis belongs to inflammation. This study included 91 patients (median age, 60 [56; 66] years) with stable exertional angina after an elective CSP using second-generation stents. Follow-up coronarography was performed for 60 patients at 12 months. Concentration of hsCRP was measured immediately prior to CSP and at 1, 3, 6, and 12 months after CSP. Restenosis of the stented segment (50% or more narrowing of the stented segment or a 5-mm vessel segment proximally or distally adjacent to the stented segment) was observed in 8 patients.

Results According to results of the ROC analysis, the increase in hsCRP concentration >0.9 mg/l (>25%) at one month after CSP had the highest predictive significance with respect of restenosis (area under the ROC curve, 0.89 at 95 % confidence interval (CI) from 0.79 to 0.99; sensitivity, 87.5 %; specificity, 82.8 %; р=0.0005), which was superior to the absolute value of hsCRP concentration >3.0 mg/l (area under the ROC curve, 0.82 at 95 % CI from 0.68 to 0.96; р=0.0007).

Conclusion      Increased concentration of hsCRP ≥0.9 mg /l (≥25 %) at a month after CSP was associated with restenosis of the coronary artery stented segment.

1. Andersson C, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-year legacy of the Framingham Heart Study. Nature Reviews Cardiology. 2019;16(11):687–98. DOI: 10.1038/s41569-019-0202-5

2. Oinotkinova O.Sh., Nikonov E.L., Kryukov E.V., Baranov A.P., Voevoda M.I. Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice. Cardiovascular Therapy and Prevention. 2019;18(6):88–98. DOI: 10.15829/1728-8800-2019-6-88-98

3. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS et al. Atherosclerosis. Nature Reviews Disease Primers. 2019;5(1):56. DOI: 10.1038/s41572-019-0106-z

4. Potekhina AV, Pylaeva E, Provatorov S, Ruleva N, Masenko V, Noeva E et al. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. Atherosclerosis. 2015;238(1):17– 21. DOI: 10.1016/j.atherosclerosis.2014.10.088

5. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clinical Science. 2018;132(12):1243–52. DOI: 10.1042/CS20180306

6. Xience P. M. S. Group, PROMUS Element/Element Plus P.M.S. Group, Kozuma K, Kozuma K, Shinozaki T, Kashiwabara K et al. Multivariable prediction model to estimate the probability of restenosis at proximal edge after 2nd-generation drug-eluting-stent implantation: development and internal validation using a quantitative coronary angiography from the post-marketing surveillance studies of everolimus-eluting stent in Japan. Cardiovascular Intervention and Therapeutics. 2020; [Epub ahead of print]. DOI: 10.1007/s12928-020-00666-2

7. Faggioni M, Baber U, Afshar AE, Giustino G, Sartori S, Sorrentino S et al. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With DrugEluting Stents. JACC: Cardiovascular Interventions. 2018;11(1):68– 76. DOI: 10.1016/j.jcin.2017.06.060

8. Geng N, Su G, Wang S, Zou D, Pang W, Sun Y. High red blood cell distribution width is closely associated with in-stent restenosis in patients with unstable angina pectoris. BMC Cardiovascular Disorders. 2019;19(1):175. DOI: 10.1186/s12872-019-1159-3

9. Wang Z, Liu C, Fang H. Blood Cell Parameters and Predicting Coronary In-Stent Restenosis. Angiology. 2019;70(8):711–8. DOI: 10.1177/0003319719830495

10. Bronze L. C-reactive protein/albumin ratio in the assessment of risk for in-stent restenosis: another small piece in the puzzle of vascular inflammation. Revista Portuguesa de Cardiologia. 2019;38(4):279–80. DOI: 10.1016/j.repc.2019.04.007

11. Rencuzogullari I, Karabağ Y, Çağdaş M, Karakoyun S, Seyis S, Gürsoy MO et al. Assessment of the relationship between preprocedural C-reactive protein/albumin ratio and stent restenosis in patients with ST-segment elevation myocardial infarction. Revista Portuguesa de Cardiologia. 2019;38(4):269–77. DOI: 10.1016/j.repc.2018.08.008

12. Filatova AYu, Pylaeva EA, Potekhina AV, Ruleva NYu, Klesareva EA, Radyukhina NV et al. Low Blood Content of IL-10-Producing CD4+ T Cells as a Risk Factor for Progression of Coronary Atherosclerosis. Bulletin of Experimental Biology and Medicine. 2019;166(3):330–3. DOI: 10.1007/s10517-019-04344-z

13. Kazmierczak E, Grajek S, Kowal J, Chmara E, Grygier M, Pyda M et al. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. European Review for Medical and Pharmacological Sciences. 2014;18(15):2169–75. PMID: 25070823

14. Haybar H, Sadegh Pezeshki SM, Saki N. Platelets in In-stent Restenosis: From Fundamental Role to Possible Prognostic Application. Current Cardiology Reviews. 2019;15. [Epub ahead of print]. DOI: 10.2174/1573403X15666190620141129

15. Wu Y, Fu X. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation. Journal of Clinical Laboratory Analysis. 2019;33(2):e22666. DOI: 10.1002/jcla.22666

16. Sumarokov A.B., Naumov V.G., Masenko V.P. C-reactive protein and cardiovascular disease. -Tver: OOO ‘Triada’;2006. -180 p. ISBN 978-5-94789-150-8

17. Libby P. Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy. New England Journal of Medicine. 2013;368(21):2004–13. DOI: 10.1056/NEJMra1216063

18. Obradovic MM, Trpkovic A, Bajic V, Soskic S, Jovanovic A, Stanimirovic J et al. Interrelatedness between C-reactive protein and oxidized low-density lipoprotein. Clinical Chemistry and Laboratory Medicine (CCLM). 2015;53(1):29–34. DOI: 10.1515/cclm-2014-0590

19. Fujita Y, Kakino A, Harada-Shiba M, Sato Y, Otsui K, Yoshimoto R et al. C-Reactive Protein Uptake by Macrophage Cell Line via ClassA Scavenger Receptor. Clinical Chemistry. 2010;56(3):478–81. DOI: 10.1373/clinchem.2009.140202

20. Qamirani E, Ren Y, Kuo L, Hein TW. C-Reactive Protein Inhibits Endothelium-Dependent NO-Mediated Dilation in Coronary Arterioles by Activating p38 Kinase and NAD(P)H Oxidase. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(5):995–1001. DOI: 10.1161/01.ATV.0000159890.10526.1e

21. Paul A, Ko KWS, Li L, Yechoor V, McCrory MA, Szalai AJ et al. C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice. Circulation. 2004;109(5):647–55. DOI: 10.1161/01.CIR.0000114526.50618.24

22. Peikert A, Kaier K, Merz J, Manhart L, Schäfer I, Hilgendorf I et al. Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort. Clinical Research in Cardiology. 2020;109(3):315–23. DOI: 10.1007/s00392-019-01511-0

23. Liu H-H, Cao Y-X, Sun D, Jin J-L, Zhang H-W, Guo Y-L et al. Highsensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. Hypertension Research. 2019;42(11):1783–93. DOI: 10.1038/s41440-019-0293-8

24. Tong DC, Whitbourn R, MacIsaac A, Wilson A, Burns A, Palmer S et al. High-Sensitivity C-Reactive Protein Is a Predictor of Coronary Microvascular Dysfunction in Patients with Ischemic Heart Disease. Frontiers in Cardiovascular Medicine. 2018;4:81. DOI: 10.3389/fcvm.2017.00081

25. Oemrawsingh RM, Cheng JM, Akkerhuis KM, Kardys I, Degertekin M, van Geuns R-J et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention. 2016;12(3):345–51. DOI: 10.4244/EIJY15M07_04

26. Zhu X, Chen Y, Xiang L, You T, Jiao Y, Xu W et al. The long-term prognostic significance of high-sensitive C-reactive protein to instent restenosis. Medicine. 2018;97(27):e10679. DOI: 10.1097/ MD.0000000000010679

27. Li X, Guo D, Zhou H, Hu Y, Fang X, Chen Y et al. Pro-inflammatory cytokines, oxidative stress and diffuse coronary reocclusions in elderly patients after coronary stenting. Cytokine. 2020;129:155028. DOI: 10.1016/j.cyto.2020.155028

28. Shen Y, Li C, Zhang RY, Zhang Q, Shen WF, Ding FH et al. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells. International Journal of Cardiology. 2017;228:129–36. DOI: 10.1016/j.ijcard.2016.11.034

29. Tscharre M, Vogel B, Tentzeris I, Freynhofer M, Rohla M, Wojta J et al. Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis. 2019;119(2):340–7. DOI: 10.1055/s-0038-1676563

30. Moon AR, Choi D-H, Jahng S-Y, Kim B-B, Seo H-J, Kim SH et al. High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for longterm clinical outcomes: a comparable and additive study. Blood Coagulation & Fibrinolysis. 2016;27(1):70–6. DOI: 10.1097/MBC.0000000000000398

31. Ogita M, Miyauchi K, Kasai T, Doi S, Wada H, Naito R et al. Impact of preprocedural high-sensitive C-reactive protein levels on longterm clinical outcomes of patients with stable coronary artery disease and chronic kidney disease who were treated with drug-eluting stents. Journal of Cardiology. 2015;66(1):15–21. DOI: 10.1016/j.jjcc.2014.10.010

32. Dan K, Miyoshi T, Nakahama M, Mizuno T, Kagawa K, Naito Y et al. Impact of Chronic Kidney Disease on Cardiovascular and Renal Events in Patients Undergoing Percutaneous Coronary Intervention with Everolimus-Eluting Stent: Risk Stratification with CReactive Protein. Cardiorenal Medicine. 2018;8(2):151–9. DOI: 10.1159/000486971

33. Shchinova A.M., Shlevkova G.V., Filatova A.Yu., Potekhina A.V., Osokina A.K., Romasov I.V. et al. Preprocedural high-sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting. Therapeutic Archive. 2019;91(9):10–5. DOI: 10.26442/00403660.2019.09.000144

34. Sun J, Yu H, Liu H, Pu D, Gao J, Jin X et al. Correlation of pre‐operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug‐eluting stents. Journal of Clinical Laboratory Analysis. 2020;34(3):e23108. DOI: 10.1002/jcla.23108

35. Cheng G, Chang F, Wang Y, You P-H, Chen H, Han W et al. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up. Medical Science Monitor. 2019;25:240–7. DOI: 10.12659/MSM.908692

36. Seo D-J, Kim Y-K, Seo Y-H, Song I-G, Kim K-H, Kwon T-G et al. Instent restenosis-prone coronary plaque composition: A retrospective virtual histology-intravascular ultrasound study. Cardiology Journal. 2018;25(1):7–13. DOI: 10.5603/CJ.a2017.0124

37. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–28. DOI: 10.1016/S0140-6736(17)32814-3

38. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA et al. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224–33. DOI: 10.1161/CIRCULATIONAHA.115.018381

39. Quispe R, Michos ED, Martin SS, Puri R, Toth PP, Al Suwaidi J et al. High‐Sensitivity C‐Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. Journal of the American Heart Association. 2020;9(3):e013600. DOI: 10.1161/JAHA.119.013600